{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:45:14Z","timestamp":1787795114952,"version":"build-2784847793"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01206","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T04:35:21Z","timestamp":1559277321000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial"],"prefix":"10.3389","volume":"10","author":[{"given":"Donald T.","family":"Weed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Zilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isildinha M.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoukaa","family":"Sargi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Abouyared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen R.","family":"Gomez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Civantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla P.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1200\/jco.2007.15.0102","article-title":"Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma","volume":"26","author":"Janot","year":"2008","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005537-200003001-00001","article-title":"Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?","volume":"110","author":"Goodwin","year":"2000","journal-title":"Laryngoscope."},{"key":"B5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2018.36.5_suppl.92","article-title":"Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced\/metastatic pancreatic cancer: Correlation with blood monocyte counts","volume":"36","author":"Linehan","year":"2018","journal-title":"J Clinl Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s40265-014-0305-6","article-title":"Clinical impact of checkpoint inhibitors as novel cancer therapies","volume":"74","author":"Shih","year":"2014","journal-title":"Drugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"w14625","DOI":"10.4414\/smw.2018.14625","article-title":"Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions","volume":"148","author":"Rothschild","year":"2018","journal-title":"Swiss Med Wkly."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/jco.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ijrobp.2017.12.300","article-title":"Two-year update from checkmate 141: outcomes with nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN) in the overall population and PD-L1 subgroups","volume":"100","author":"Ferris","year":"2018","journal-title":"Int J Rad Oncol Biol Phys."},{"key":"B10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/TCRM.S125059","article-title":"New developments in the management of head and neck cancer - impact of pembrolizumab","volume":"14","author":"Saleh","year":"2018","journal-title":"Therapeut Clin Risk Manag."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e18020","DOI":"10.1200\/JCO.2018.36.15_suppl.e18020","article-title":"Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib\/II trial (N16IMC, NCT03003637)","volume":"36","author":"Zuur","year":"2018","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science."},{"key":"B13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J ImmunoTher Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.oraloncology.2017.12.003","article-title":"Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent\/recurrent laryngeal squamous cell carcinoma","volume":"77","author":"Hoesli","year":"2018","journal-title":"Oral oncology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1247135","DOI":"10.1080\/2162402X.2016.1247135","article-title":"The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells","volume":"5","author":"Lu","year":"2016","journal-title":"Oncoimmunology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1155\/2017\/1506824","article-title":"Dynamics of neutrophils-to-lymphocyte ratio predict outcomes of PD-1\/PD-L1 blockade","volume":"2017","author":"Moschetta","year":"2017","journal-title":"BioMed Res Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.11.012","article-title":"Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1\/PD-L1 inhibitors","volume":"89","author":"Ameratunga","year":"2018","journal-title":"Eur J Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/jcm7100294","article-title":"Predictive value of the pretreatment neutrophil-to-lymphocyte ratio in head and neck squamous cell carcinoma","volume":"7","author":"Chen","year":"2018","journal-title":"J Clin Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00262-018-2192-2","article-title":"Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer","volume":"67","author":"Parikh","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e21165","DOI":"10.1200\/JCO.2018.36.15_suppl.e21165","article-title":"Monocytes and neutrophils as a predictive marker of response to immune checkpoint inhibitors (ICI) in metastatic non-small cell lung cancer (mNSCLC)","volume":"36","author":"Parikh","year":"2018","journal-title":"J Clin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OTT.S153290","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis","volume":"11","author":"Sacdalan","year":"2018","journal-title":"OncoTargets Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1164\/rccm.201808-1502LE","article-title":"The ratio of peripheral regulatory T cells to Lox-1(+) polymorphonuclear myeloid-derived suppressor cells predicts the early response to Anti-PD-1 therapy in patients with non-small cell lung cancer","volume":"199","author":"Kim","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12026-013-8455-2","article-title":"Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly","volume":"57","author":"Serafini","year":"2013","journal-title":"Immunol Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/vaccines4030031","article-title":"Neutrophils and granulocytic MDSC: the janus god of cancer immunotherapy","volume":"4","author":"Zilio","year":"2016","journal-title":"Vaccines."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1158\/0008-5472.Can-16-2534","article-title":"Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kdelta\/gamma","volume":"77","author":"Davis","year":"2017","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J Exp Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","article-title":"Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells","volume":"68","author":"Serafini","year":"2008","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2172-10-1","article-title":"Modulators of arginine metabolism support cancer immunosurveillance","volume":"10","author":"Capuano","year":"2009","journal-title":"BMC Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"17111","DOI":"10.1073\/pnas.1108121108","article-title":"Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model","volume":"108","author":"Meyer","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1158\/1078-0432.Ccr-10-2547","article-title":"Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer","volume":"17","author":"Rigamonti","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00262-016-1878-6","article-title":"Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG","volume":"65","author":"Confino","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.ccr-14-1716","article-title":"Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Califano","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.ccr-14-1711","article-title":"Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Weed","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1258\/0022215001904121","article-title":"muc-1 gene expression in head and neck squamous cell carcinomas","volume":"114","author":"Rubin","year":"2000","journal-title":"J Laryngol Otol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1053\/paor.2001.0338","article-title":"MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma","volume":"7","author":"Croce","year":"2001","journal-title":"Pathol Oncol Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/BF02893370","article-title":"Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma","volume":"11","author":"Croce","year":"2005","journal-title":"Pathol Oncol Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00262-006-0242-7","article-title":"Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma","volume":"56","author":"Young","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/hed.20756","article-title":"Differential expression of MUC1 and carbohydrate antigens in primary and secondary head and neck squamous cell carcinoma","volume":"30","author":"Croce","year":"2008","journal-title":"Head Neck."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1002\/cncr.27542","article-title":"DF3 epitope expression on MUC1 mucin is associated with tumor aggressiveness, subsequent lymph node metastasis, and poor prognosis in patients with oral squamous cell carcinoma","volume":"118","author":"Hamada","year":"2012","journal-title":"Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"96359","DOI":"10.18632\/oncotarget.19648","article-title":"Prognostic and clinicopathological significance of MUC expression in head and neck cancer: a systematic review and meta-analysis","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1172\/JCI37646","article-title":"Rapid T cell\u2013based identification of human tumor tissue antigens by automated two-dimensional protein fractionation","volume":"120","author":"Beckhove","year":"2010","journal-title":"J Clin Investig."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1016\/j.vaccine.2011.04.103","article-title":"ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors","volume":"29","author":"Kovjazin","year":"2011","journal-title":"Vaccine."},{"key":"B44","doi-asserted-by":"publisher","first-page":"791","DOI":"10.4161\/onci.19863","article-title":"TG4010: A therapeutic vaccine against MUC1 expressing tumors","volume":"1","author":"Limacher","year":"2012","journal-title":"Oncoimmunology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/nyas.12108","article-title":"Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas","volume":"1284","author":"Beatty","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1517\/14712598.2012.725719","article-title":"MUC1 immunotherapy is here to stay","volume":"13","author":"Kimura","year":"2013","journal-title":"Expert Opin Biol Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"105284","DOI":"10.18632\/oncotarget.22168","article-title":"Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-kappaB p65 and EzH2, in colitis-associated cancer","volume":"8","author":"Cascio","year":"2017","journal-title":"Oncotarget."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/0194599818818443","article-title":"Salvage surgery for recurrence after radiotherapy for squamous cell carcinoma of the head and neck","author":"Elbers","year":"2018","journal-title":"Otolaryngol Head Neck Surgery"},{"key":"B50","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Sci Immunol."},{"key":"B51","first-page":"5344","article-title":"Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma","volume":"58","author":"Reichert","year":"1998","journal-title":"Cancer Res."},{"key":"B52","first-page":"329","article-title":"Clinical Significance of Decreased \u03b6 Chain Expression in Peripheral Blood Lymphocytes of Patients with Head and Neck Cancer","volume":"5","author":"Kuss","year":"1999","journal-title":"Clinical Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodr\u00edguez","year":"2008","journal-title":"Immunol Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3892\/or.2018.6288","article-title":"IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides","volume":"39","author":"Kanekiyo","year":"2018","journal-title":"Oncol Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e71908","DOI":"10.1371\/journal.pone.0071908","article-title":"FOXP3 subcellular localization predicts recurrence in oral squamous cell carcinoma","volume":"8","author":"Weed","year":"2013","journal-title":"PLoS ONE."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/eji.201141838","article-title":"Subcellular localization of FOXP3 in human regulatory and nonregulatory T cells","volume":"42","author":"Magg","year":"2012","journal-title":"Eur J Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/jci91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest."},{"key":"B59","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fonc.2018.00532","article-title":"Crosstalk between PD-1\/PD-L1 blockade and its combinatorial therapies in tumor immune microenvironment: a focus on HNSCC","volume":"8","author":"Lin","year":"2018","journal-title":"Front Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10549-016-4013-7","article-title":"miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients","volume":"160","author":"Lanczky","year":"2016","journal-title":"Breast Cancer Res Treat."},{"key":"B61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3816\/CLM.2004.n.029","article-title":"Clinical responses to sildenafil in Waldenstrom's macroglobulinemia","volume":"5","author":"Treon","year":"2004","journal-title":"Clin Lymphoma."},{"key":"B62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2002-01-0075","article-title":"Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells","volume":"101","author":"Sarfati","year":"2003","journal-title":"Blood."},{"key":"B63","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/0973-1482.27589","article-title":"A new indication of sildenafil in medicine: hypoxic cell sensitizer for penile cancer","volume":"2","author":"Huilgol","year":"2006","journal-title":"J Cancer Res Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/2326-6066.Cir-13-0213","article-title":"Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma","volume":"2","author":"Noonan","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1326440","DOI":"10.1080\/2162402x.2017.1326440","article-title":"Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)","volume":"6","author":"Hassel","year":"2017","journal-title":"Oncoimmunology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"97920","DOI":"10.18632\/oncotarget.18542","article-title":"Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma","volume":"8","author":"Ock","year":"2017","journal-title":"Oncotarget."},{"key":"B67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01206\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T04:35:24Z","timestamp":1559277324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01206\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2019.01206"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01206","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"article-number":"1206"}}